Abstract:Greater intakes of micronutrients and minerals such as vitamin D, calcium, and magnesium have long been associated with decreased incidence of many late-onset disorders in observational studies (1–5), although large randomized intervention trials that directly evaluate their clinical efficacies have generated inconsistent results (6–8). Nevertheless, some observations have been well recognized, including high prevalence of vitamin D and magnesium insufficiency in westernized populations (9, 10) and the large interpersonal variations of vitamin D and magnesium metabolisms in the general population (11). Studies have shown that magnesium plays a critically important role in the synthesis and metabolism of vitamin D, raising the possibility that magnesium should be included in any vitamin D regimen for optimal biological functioning (12). In this issue of the Journal, Dai et al. (13) report very interesting findings from a randomized trial showing that 12 wk of magnesium supplementation using a personalized dosing scheme adjusted to participants’ dietary intakes significantly changed vitamin D metabolism dependent upon vitamin D status at baseline. Specifically, concentrations of 25-hydroxycholecalciferol [25(OH)D3] were found to increase among those whose baseline concentrations of 25-hydroxyvitamin D [25(OH)D] were <30 ng/mL but decrease among those whose concentrations of 25(OH)D were in the range of 30–50 ng/mL. More interestingly, magnesium supplementation also appeared to selectively deactivate cytochrome P450 3A4 (CYP34A) to degrade vitamin D3 over D2 when plasma 25(OH)D was high. These data therefore provide for the first time some tantalizing evidence in support of the notion that adequate magnesium status could directly improve vitamin D deficiency and its related adverse events. Dai et al. (13) also noted that all trial participants at baseline had a Ca:Mg intake ratio >2.6, which was reduced to 2.3 after being given magnesium supplementation. However, whether a 3-way interaction of calcium–magnesium–vitamin D existed and how it might have influenced the effects of the magnesium dosing strategy on vitamin D metabolites were not explored, probably owing to statistical inefficacy. Moreover, other limitations also need to be kept in mind when interpreting these findings. First, dietary intakes were assessed via 24-h recall, and measurement error was likely to affect the estimates of the Ca:Mg intake ratios reported. It would have been informative if the status of calcium and magnesium had also been assessed using biomarkers in different tissues (urine, plasma, and red blood cells). Second, the exact number of participants in each stratum of baseline 25(OH)D concentrations (<12, 20, 30, 40, 50, >50 ng/mL) was not reported but is likely to be small. As acknowledged by the authors, there were only 2 participants with baseline 25(OH)D <12 ng/mL, making it powerless to determine any magnesium–vitamin D interaction among those with such low concentrations at baseline. Similarly, findings of 25(OH)D2 had wide 95% CIs among those whose baseline 25(OH)D was >50 ng/mL. Moreover, 2 other vitamin D metabolites— 25(OH)D3 and 24,25-dihydroxyvitamin D3—appeared to decrease after magnesium supplementation among those with baseline 25(OH)D at 50 ng/mL, whereas when baseline 25(OH)D concentrations were <30 mg/mL, 25(OH)D3 increased, but not for 24,25-dihydroxyvitamin D3. These observations raise the possibility that both false positives and false negatives were possible alternative explanations for their findings. In fact, of the 265 participants who met the inclusion criteria and were randomly assigned, 239 completed the study and only 180 (68% of enrolled participants) were included in the current analysis. To improve statistical efficiency, the authors opted for not carrying out an intent-to-treat analysis, abolishing the randomization design. As such, the effect size measure for magnesium–vitamin D interaction may have been biased, particularly for those with baseline 25(OH)D3 ≥30 ng/mL. Finally, trial participants had previously been diagnosed with colorectal adenomas or hyperplastic polyps (and 14 participants were polyp-free individuals with a high risk of colorectal cancer), thus they were clearly not representative of the general population

Randomized study of the effects of vitamin D and/or magnesium supplementation on mood, serum levels of BDNF, inflammation, and SIRT1 in obese women with mild to moderate depressive symptoms

The effect of vitamin D and magnesium supplementation on clinical symptoms and serum inflammatory and oxidative stress markers in patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial

Magnesium supplementation beneficially affects depression in adults with depressive disorder: a systematic review and meta-analysis of randomized clinical trials

Dietary intake with supplementation of vitamin D, vitamin B6, and magnesium on depressive symptoms: a public health perspective

Effects of zinc and magnesium supplements on postpartum depression and anxiety: A randomized controlled clinical trial

The effect of vitamin D and calcium supplementation on inflammatory biomarkers, estradiol levels and severity of symptoms in women with postpartum depression: a randomized double-blind clinical trial

Effects of vitamin D supplementation on depressive symptoms in type 2 diabetes mellitus patients: Randomized placebo-controlled double-blind clinical trial

Database Analysis of Depression and Anxiety in a Community Sample-Response to a Micronutrient Intervention

Effect of omega‐3 and vitamin D co‐supplementation on psychological distress in reproductive‐aged women with pre‐diabetes and hypovitaminosis D: A randomized controlled trial

The effects of magnesium-zinc-calcium-vitamin D co-supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes

The influences of vitamin D and omega-3 co-supplementation on clinical, metabolic and genetic parameters in women with polycystic ovary syndrome

Vitamin D Supplementation for the Treatment of Depressive Symptoms in Women with Type 2 Diabetes: A Randomized Clinical Trial

Effect of vitamin D supplementation on depression in older Australian adults

Effects of nutritional interventions on the severity of depressive and anxiety symptoms of women in the menopausal transition and menopause: a systematic review, meta-analysis, and meta-regression

The effect of vitamin D supplementation on depression: a systematic review and dose–response meta-analysis of randomized controlled trials

The Effects of Magnesium and Vitamin E Co-Supplementation on Hormonal Status and Biomarkers of Inflammation and Oxidative Stress in Women with Polycystic Ovary Syndrome

Personalized Magnesium Intervention to Improve Vitamin D Metabolism: Applying a Systems Approach for Precision Nutrition in Large Randomized Trials of Diverse Populations.

Effect of long-term supplementation with folic acid and B vitamins on risk of depression in older women

Efficacy of vitamin D supplementation on depressive symptoms in older patients: a meta-analysis of randomized controlled trials

Melatonin Effects in Women With Comorbidities of Overweight, Depression, and Sleep Disturbance: A Randomized Placebo Controlled Clinical Trial

Serum Ghrelin and Leptin Concentrations in Patients with Major Depressive Disorder before and after Supplementation with Vitamin D3